Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C58H80N16O14.C2H4O2 |
| Molecular Weight | 1285.4066 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.[H][C@]1(C[C@@H](O)CN1C(=O)[C@@H](CC2=CC=C(O)C=C2)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)NC)C(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(N)=O
InChI
InChIKey=ITKNOAGWRWNSIK-NHDJLUSCSA-N
InChI=1S/C58H80N16O14.C2H4O2/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34;1-2(3)4/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88);1H3,(H,3,4)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+;/m1./s1
| Molecular Formula | C58H80N16O14 |
| Molecular Weight | 1225.3546 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 4 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C2H4O2 |
| Molecular Weight | 60.052 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
TAK-448 is an investigational oligopeptide analog of kisspeptin and a potent agonist of the GPR54 receptor. In animals, acute TAK-448 administration stimulates luteinizing hormone (LH)/follicle-stimulating hormone release, whereas continuous subcutaneous exposure rapidly down-regulates the pituitary-gonadal axis, with rapid reduction of testosterone levels in a dose-dependent manner. TAK-448 has exhibited potent antitumor activity in rat androgen-dependent prostate cancer models. In accordance with the T reductions, TAK-448 treatment showed also more rapid reduction in plasma prostate-specific antigen(PSA) levels. TAK-448 had been in phase II clinical trials for the treatment of prostate cancer. However, this research has been discontinued.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:14:31 GMT 2023
by
admin
on
Sat Dec 16 09:14:31 GMT 2023
|
| Record UNII |
F5X2S8T7CV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1470374-22-1
Created by
admin on Sat Dec 16 09:14:31 GMT 2023 , Edited by admin on Sat Dec 16 09:14:31 GMT 2023
|
PRIMARY | |||
|
DBSALT002114
Created by
admin on Sat Dec 16 09:14:31 GMT 2023 , Edited by admin on Sat Dec 16 09:14:31 GMT 2023
|
PRIMARY | |||
|
F5X2S8T7CV
Created by
admin on Sat Dec 16 09:14:31 GMT 2023 , Edited by admin on Sat Dec 16 09:14:31 GMT 2023
|
PRIMARY | |||
|
91668185
Created by
admin on Sat Dec 16 09:14:31 GMT 2023 , Edited by admin on Sat Dec 16 09:14:31 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |